Global Anti-inflammatory Drugs

Anti-inflammatory Drugs Comprehensive Study by Type (Aspirin,, Ibuprofen, Naproxen, COX-2 Inhibitors, Other), Application (Skin Rashes, Chronic Arthritis, Other), Treatment (Arthritis, Chronic obstructive pulmonary disease (COPD), Multiple Sclerosis, Inflammatory bowel disease (IBD), Asthma, Others), Form (Regular Tablet, Delayed-Release Tablet, Liquid, Topical Cream, Paste, Injection), Distribution Channel (Online, Offline), Method (Over-The-Counter, Prescription Medications), Drug Class (Anti-Inflammatory Biologics, Nonsteroidal anti-inflammatory drugs (NSAIDs), Corticosteroids, Immune-selective anti-inflammatory derivative (ImSAID), Others) Players and Region - Global Market Outlook to 2028

Anti-inflammatory Drugs Market by XX Submarkets | Forecast Years 2023-2028  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Anti-inflammatory Drugs
Anti-inflammatory drugs or substances used to reduce inflammation in the body by blocking certain substances in the body that cause inflammation. They are used to treat several conditions, some of them are being studied in the prevention and treatment of cancer, asthma, arthritis, chronic obstructive pulmonary, and other. The growing prevalence of these diseases is the key factor for booming market growth.

AttributesDetails
Study Period2018-2028
Base Year2022
UnitValue (USD Million)


The greater part of the Anti-Inflammatory drugs is being manufactured by the global key players. Market privileged with more funds for research and a better distribution system has established its position in the market. The foremost companies along with their product portfolios, marketing strategy, latest advancements, company profile, and market strategies to enhance their market share. and . Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Anti-inflammatory Drugs market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

Roche (Switzerland), Abbott Laboratories (United States), Johnson & Johnson (United States), Merck & Co. (United States), Pfizer (United States), Amgen(United States), Sanofi (France), Novartis (Switzerland), Eli Lilly and Company(United States) and Amgen(United States) are some of the key players that are part of study coverage. Additionally, the Players which are also part of the research coverage are Bayer (Germany) and Novacap (Canada).

Segmentation Overview
AMA Research has segmented the market of Global Anti-inflammatory Drugs market by Type (Aspirin,, Ibuprofen, Naproxen, COX-2 Inhibitors and Other), Application (Skin Rashes, Chronic Arthritis and Other) and Region.



On the basis of geography, the market of Anti-inflammatory Drugs has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Arthritis will boost the Anti-inflammatory Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Form, the sub-segment i.e. Regular Tablet will boost the Anti-inflammatory Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Distribution Channel, the sub-segment i.e. Online will boost the Anti-inflammatory Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Method, the sub-segment i.e. Over-The-Counter will boost the Anti-inflammatory Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Drug Class, the sub-segment i.e. Anti-Inflammatory Biologics will boost the Anti-inflammatory Drugs market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Market Growth Drivers:
Increasing Incidences of Autoimmune and Respiratory Conditions and Mounting Awareness Of Anti-Inflammatory Therapeutics And Attractive Government Inventiveness Are Expected To Drive The Overall Market.

Challenges:
Patent Expiration will increase the competition between providers

Restraints:
Adverse Effects of Anti-Inflammatory Drugs

Opportunities:
Increasing Research for Safer New Anti-Inflammatory Drugs and Government involvement is booming the opportunities of growth of the market.

Market Leaders and their expansionary development strategies
In December 2020 johnson & Johnson United States-based company announced their acquisition agreement of acquiring the remaining stake of Verb Surgical Inc. This acquisition will help the company to strengthen its digital surgery portfolio across the globe
On 20 March 2020 on NSAIDs and viral respiratory infections using MEDLINE, and EMBASE, and WHO Global Database. The review included studies conducted in humans of any age with viral respiratory infections exposed to systemic NSAIDs of any kind. All studies on COVID-19, the Middle East Respiratory Syndrome (MERS), and Severe Acute Respiratory Syndrome (SARS) were included irrespective of their sample size.


Key Target Audience
New Entrants/Investors, Analysts and Strategic Business Planners, Enterprise Infrastructure Servers Developer, Dealers, Suppliers, Traders, and Distributors, Venture Capitalists and Private Equity Firms and Government Regulatory and Research Organizations

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Type
  • Aspirin,
  • Ibuprofen
  • Naproxen
  • COX-2 Inhibitors
  • Other
By Application
  • Skin Rashes
  • Chronic Arthritis
  • Other
By Treatment
  • Arthritis
  • Chronic obstructive pulmonary disease (COPD)
  • Multiple Sclerosis
  • Inflammatory bowel disease (IBD)
  • Asthma
  • Others

By Form
  • Regular Tablet
  • Delayed-Release Tablet
  • Liquid
  • Topical Cream
  • Paste
  • Injection

By Distribution Channel
  • Online
  • Offline

By Method
  • Over-The-Counter
  • Prescription Medications

By Drug Class
  • Anti-Inflammatory Biologics
  • Nonsteroidal anti-inflammatory drugs (NSAIDs)
  • Corticosteroids
  • Immune-selective anti-inflammatory derivative (ImSAID)
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increasing Incidences of Autoimmune and Respiratory Conditions
      • 3.2.2. Mounting Awareness Of Anti-Inflammatory Therapeutics And Attractive Government Inventiveness Are Expected To Drive The Overall Market.
    • 3.3. Market Challenges
      • 3.3.1. Patent Expiration will increase the competition between providers
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Anti-inflammatory Drugs, by Type, Application, Treatment, Form, Distribution Channel, Method, Drug Class and Region (value, volume and price ) (2017-2022)
    • 5.1. Introduction
    • 5.2. Global Anti-inflammatory Drugs (Value)
      • 5.2.1. Global Anti-inflammatory Drugs by: Type (Value)
        • 5.2.1.1. Aspirin,
        • 5.2.1.2. Ibuprofen
        • 5.2.1.3. Naproxen
        • 5.2.1.4. COX-2 Inhibitors
        • 5.2.1.5. Other
      • 5.2.2. Global Anti-inflammatory Drugs by: Application (Value)
        • 5.2.2.1. Skin Rashes
        • 5.2.2.2. Chronic Arthritis
        • 5.2.2.3. Other
      • 5.2.3. Global Anti-inflammatory Drugs by: Treatment (Value)
        • 5.2.3.1. Arthritis
        • 5.2.3.2. Chronic obstructive pulmonary disease (COPD)
        • 5.2.3.3. Multiple Sclerosis
        • 5.2.3.4. Inflammatory bowel disease (IBD)
        • 5.2.3.5. Asthma
        • 5.2.3.6. Others
      • 5.2.4. Global Anti-inflammatory Drugs by: Form (Value)
        • 5.2.4.1. Regular Tablet
        • 5.2.4.2. Delayed-Release Tablet
        • 5.2.4.3. Liquid
        • 5.2.4.4. Topical Cream
        • 5.2.4.5. Paste
        • 5.2.4.6. Injection
      • 5.2.5. Global Anti-inflammatory Drugs by: Distribution Channel (Value)
        • 5.2.5.1. Online
        • 5.2.5.2. Offline
      • 5.2.6. Global Anti-inflammatory Drugs by: Method (Value)
        • 5.2.6.1. Over-The-Counter
        • 5.2.6.2. Prescription Medications
      • 5.2.7. Global Anti-inflammatory Drugs by: Drug Class (Value)
        • 5.2.7.1. Anti-Inflammatory Biologics
        • 5.2.7.2. Nonsteroidal anti-inflammatory drugs (NSAIDs)
        • 5.2.7.3. Corticosteroids
        • 5.2.7.4. Immune-selective anti-inflammatory derivative (ImSAID)
        • 5.2.7.5. Others
      • 5.2.8. Global Anti-inflammatory Drugs Region
        • 5.2.8.1. South America
          • 5.2.8.1.1. Brazil
          • 5.2.8.1.2. Argentina
          • 5.2.8.1.3. Rest of South America
        • 5.2.8.2. Asia Pacific
          • 5.2.8.2.1. China
          • 5.2.8.2.2. Japan
          • 5.2.8.2.3. India
          • 5.2.8.2.4. South Korea
          • 5.2.8.2.5. Taiwan
          • 5.2.8.2.6. Australia
          • 5.2.8.2.7. Rest of Asia-Pacific
        • 5.2.8.3. Europe
          • 5.2.8.3.1. Germany
          • 5.2.8.3.2. France
          • 5.2.8.3.3. Italy
          • 5.2.8.3.4. United Kingdom
          • 5.2.8.3.5. Netherlands
          • 5.2.8.3.6. Rest of Europe
        • 5.2.8.4. MEA
          • 5.2.8.4.1. Middle East
          • 5.2.8.4.2. Africa
        • 5.2.8.5. North America
          • 5.2.8.5.1. United States
          • 5.2.8.5.2. Canada
          • 5.2.8.5.3. Mexico
    • 5.3. Global Anti-inflammatory Drugs (Volume)
      • 5.3.1. Global Anti-inflammatory Drugs by: Type (Volume)
        • 5.3.1.1. Aspirin,
        • 5.3.1.2. Ibuprofen
        • 5.3.1.3. Naproxen
        • 5.3.1.4. COX-2 Inhibitors
        • 5.3.1.5. Other
      • 5.3.2. Global Anti-inflammatory Drugs by: Application (Volume)
        • 5.3.2.1. Skin Rashes
        • 5.3.2.2. Chronic Arthritis
        • 5.3.2.3. Other
      • 5.3.3. Global Anti-inflammatory Drugs by: Treatment (Volume)
        • 5.3.3.1. Arthritis
        • 5.3.3.2. Chronic obstructive pulmonary disease (COPD)
        • 5.3.3.3. Multiple Sclerosis
        • 5.3.3.4. Inflammatory bowel disease (IBD)
        • 5.3.3.5. Asthma
        • 5.3.3.6. Others
      • 5.3.4. Global Anti-inflammatory Drugs by: Form (Volume)
        • 5.3.4.1. Regular Tablet
        • 5.3.4.2. Delayed-Release Tablet
        • 5.3.4.3. Liquid
        • 5.3.4.4. Topical Cream
        • 5.3.4.5. Paste
        • 5.3.4.6. Injection
      • 5.3.5. Global Anti-inflammatory Drugs by: Distribution Channel (Volume)
        • 5.3.5.1. Online
        • 5.3.5.2. Offline
      • 5.3.6. Global Anti-inflammatory Drugs by: Method (Volume)
        • 5.3.6.1. Over-The-Counter
        • 5.3.6.2. Prescription Medications
      • 5.3.7. Global Anti-inflammatory Drugs by: Drug Class (Volume)
        • 5.3.7.1. Anti-Inflammatory Biologics
        • 5.3.7.2. Nonsteroidal anti-inflammatory drugs (NSAIDs)
        • 5.3.7.3. Corticosteroids
        • 5.3.7.4. Immune-selective anti-inflammatory derivative (ImSAID)
        • 5.3.7.5. Others
      • 5.3.8. Global Anti-inflammatory Drugs Region
        • 5.3.8.1. South America
          • 5.3.8.1.1. Brazil
          • 5.3.8.1.2. Argentina
          • 5.3.8.1.3. Rest of South America
        • 5.3.8.2. Asia Pacific
          • 5.3.8.2.1. China
          • 5.3.8.2.2. Japan
          • 5.3.8.2.3. India
          • 5.3.8.2.4. South Korea
          • 5.3.8.2.5. Taiwan
          • 5.3.8.2.6. Australia
          • 5.3.8.2.7. Rest of Asia-Pacific
        • 5.3.8.3. Europe
          • 5.3.8.3.1. Germany
          • 5.3.8.3.2. France
          • 5.3.8.3.3. Italy
          • 5.3.8.3.4. United Kingdom
          • 5.3.8.3.5. Netherlands
          • 5.3.8.3.6. Rest of Europe
        • 5.3.8.4. MEA
          • 5.3.8.4.1. Middle East
          • 5.3.8.4.2. Africa
        • 5.3.8.5. North America
          • 5.3.8.5.1. United States
          • 5.3.8.5.2. Canada
          • 5.3.8.5.3. Mexico
    • 5.4. Global Anti-inflammatory Drugs (Price)
      • 5.4.1. Global Anti-inflammatory Drugs by: Type (Price)
  • 6. Anti-inflammatory Drugs: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2022)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Roche (Switzerland)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Abbott Laboratories (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Johnson & Johnson (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Merck & Co. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Pfizer (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Amgen(United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Sanofi (France)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis (Switzerland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Eli Lilly and Company(United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Amgen(United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Anti-inflammatory Drugs Sale, by Type, Application, Treatment, Form, Distribution Channel, Method, Drug Class and Region (value, volume and price ) (2023-2028)
    • 7.1. Introduction
    • 7.2. Global Anti-inflammatory Drugs (Value)
      • 7.2.1. Global Anti-inflammatory Drugs by: Type (Value)
        • 7.2.1.1. Aspirin,
        • 7.2.1.2. Ibuprofen
        • 7.2.1.3. Naproxen
        • 7.2.1.4. COX-2 Inhibitors
        • 7.2.1.5. Other
      • 7.2.2. Global Anti-inflammatory Drugs by: Application (Value)
        • 7.2.2.1. Skin Rashes
        • 7.2.2.2. Chronic Arthritis
        • 7.2.2.3. Other
      • 7.2.3. Global Anti-inflammatory Drugs by: Treatment (Value)
        • 7.2.3.1. Arthritis
        • 7.2.3.2. Chronic obstructive pulmonary disease (COPD)
        • 7.2.3.3. Multiple Sclerosis
        • 7.2.3.4. Inflammatory bowel disease (IBD)
        • 7.2.3.5. Asthma
        • 7.2.3.6. Others
      • 7.2.4. Global Anti-inflammatory Drugs by: Form (Value)
        • 7.2.4.1. Regular Tablet
        • 7.2.4.2. Delayed-Release Tablet
        • 7.2.4.3. Liquid
        • 7.2.4.4. Topical Cream
        • 7.2.4.5. Paste
        • 7.2.4.6. Injection
      • 7.2.5. Global Anti-inflammatory Drugs by: Distribution Channel (Value)
        • 7.2.5.1. Online
        • 7.2.5.2. Offline
      • 7.2.6. Global Anti-inflammatory Drugs by: Method (Value)
        • 7.2.6.1. Over-The-Counter
        • 7.2.6.2. Prescription Medications
      • 7.2.7. Global Anti-inflammatory Drugs by: Drug Class (Value)
        • 7.2.7.1. Anti-Inflammatory Biologics
        • 7.2.7.2. Nonsteroidal anti-inflammatory drugs (NSAIDs)
        • 7.2.7.3. Corticosteroids
        • 7.2.7.4. Immune-selective anti-inflammatory derivative (ImSAID)
        • 7.2.7.5. Others
      • 7.2.8. Global Anti-inflammatory Drugs Region
        • 7.2.8.1. South America
          • 7.2.8.1.1. Brazil
          • 7.2.8.1.2. Argentina
          • 7.2.8.1.3. Rest of South America
        • 7.2.8.2. Asia Pacific
          • 7.2.8.2.1. China
          • 7.2.8.2.2. Japan
          • 7.2.8.2.3. India
          • 7.2.8.2.4. South Korea
          • 7.2.8.2.5. Taiwan
          • 7.2.8.2.6. Australia
          • 7.2.8.2.7. Rest of Asia-Pacific
        • 7.2.8.3. Europe
          • 7.2.8.3.1. Germany
          • 7.2.8.3.2. France
          • 7.2.8.3.3. Italy
          • 7.2.8.3.4. United Kingdom
          • 7.2.8.3.5. Netherlands
          • 7.2.8.3.6. Rest of Europe
        • 7.2.8.4. MEA
          • 7.2.8.4.1. Middle East
          • 7.2.8.4.2. Africa
        • 7.2.8.5. North America
          • 7.2.8.5.1. United States
          • 7.2.8.5.2. Canada
          • 7.2.8.5.3. Mexico
    • 7.3. Global Anti-inflammatory Drugs (Volume)
      • 7.3.1. Global Anti-inflammatory Drugs by: Type (Volume)
        • 7.3.1.1. Aspirin,
        • 7.3.1.2. Ibuprofen
        • 7.3.1.3. Naproxen
        • 7.3.1.4. COX-2 Inhibitors
        • 7.3.1.5. Other
      • 7.3.2. Global Anti-inflammatory Drugs by: Application (Volume)
        • 7.3.2.1. Skin Rashes
        • 7.3.2.2. Chronic Arthritis
        • 7.3.2.3. Other
      • 7.3.3. Global Anti-inflammatory Drugs by: Treatment (Volume)
        • 7.3.3.1. Arthritis
        • 7.3.3.2. Chronic obstructive pulmonary disease (COPD)
        • 7.3.3.3. Multiple Sclerosis
        • 7.3.3.4. Inflammatory bowel disease (IBD)
        • 7.3.3.5. Asthma
        • 7.3.3.6. Others
      • 7.3.4. Global Anti-inflammatory Drugs by: Form (Volume)
        • 7.3.4.1. Regular Tablet
        • 7.3.4.2. Delayed-Release Tablet
        • 7.3.4.3. Liquid
        • 7.3.4.4. Topical Cream
        • 7.3.4.5. Paste
        • 7.3.4.6. Injection
      • 7.3.5. Global Anti-inflammatory Drugs by: Distribution Channel (Volume)
        • 7.3.5.1. Online
        • 7.3.5.2. Offline
      • 7.3.6. Global Anti-inflammatory Drugs by: Method (Volume)
        • 7.3.6.1. Over-The-Counter
        • 7.3.6.2. Prescription Medications
      • 7.3.7. Global Anti-inflammatory Drugs by: Drug Class (Volume)
        • 7.3.7.1. Anti-Inflammatory Biologics
        • 7.3.7.2. Nonsteroidal anti-inflammatory drugs (NSAIDs)
        • 7.3.7.3. Corticosteroids
        • 7.3.7.4. Immune-selective anti-inflammatory derivative (ImSAID)
        • 7.3.7.5. Others
      • 7.3.8. Global Anti-inflammatory Drugs Region
        • 7.3.8.1. South America
          • 7.3.8.1.1. Brazil
          • 7.3.8.1.2. Argentina
          • 7.3.8.1.3. Rest of South America
        • 7.3.8.2. Asia Pacific
          • 7.3.8.2.1. China
          • 7.3.8.2.2. Japan
          • 7.3.8.2.3. India
          • 7.3.8.2.4. South Korea
          • 7.3.8.2.5. Taiwan
          • 7.3.8.2.6. Australia
          • 7.3.8.2.7. Rest of Asia-Pacific
        • 7.3.8.3. Europe
          • 7.3.8.3.1. Germany
          • 7.3.8.3.2. France
          • 7.3.8.3.3. Italy
          • 7.3.8.3.4. United Kingdom
          • 7.3.8.3.5. Netherlands
          • 7.3.8.3.6. Rest of Europe
        • 7.3.8.4. MEA
          • 7.3.8.4.1. Middle East
          • 7.3.8.4.2. Africa
        • 7.3.8.5. North America
          • 7.3.8.5.1. United States
          • 7.3.8.5.2. Canada
          • 7.3.8.5.3. Mexico
    • 7.4. Global Anti-inflammatory Drugs (Price)
      • 7.4.1. Global Anti-inflammatory Drugs by: Type (Price)
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Anti-inflammatory Drugs: by Type(USD Million)
  • Table 2. Anti-inflammatory Drugs Aspirin, , by Region USD Million (2017-2022)
  • Table 3. Anti-inflammatory Drugs Ibuprofen , by Region USD Million (2017-2022)
  • Table 4. Anti-inflammatory Drugs Naproxen , by Region USD Million (2017-2022)
  • Table 5. Anti-inflammatory Drugs COX-2 Inhibitors , by Region USD Million (2017-2022)
  • Table 6. Anti-inflammatory Drugs Other , by Region USD Million (2017-2022)
  • Table 7. Anti-inflammatory Drugs: by Application(USD Million)
  • Table 8. Anti-inflammatory Drugs Skin Rashes , by Region USD Million (2017-2022)
  • Table 9. Anti-inflammatory Drugs Chronic Arthritis , by Region USD Million (2017-2022)
  • Table 10. Anti-inflammatory Drugs Other , by Region USD Million (2017-2022)
  • Table 11. Anti-inflammatory Drugs: by Treatment(USD Million)
  • Table 12. Anti-inflammatory Drugs Arthritis , by Region USD Million (2017-2022)
  • Table 13. Anti-inflammatory Drugs Chronic obstructive pulmonary disease (COPD) , by Region USD Million (2017-2022)
  • Table 14. Anti-inflammatory Drugs Multiple Sclerosis , by Region USD Million (2017-2022)
  • Table 15. Anti-inflammatory Drugs Inflammatory bowel disease (IBD) , by Region USD Million (2017-2022)
  • Table 16. Anti-inflammatory Drugs Asthma , by Region USD Million (2017-2022)
  • Table 17. Anti-inflammatory Drugs Others , by Region USD Million (2017-2022)
  • Table 18. Anti-inflammatory Drugs: by Form(USD Million)
  • Table 19. Anti-inflammatory Drugs Regular Tablet , by Region USD Million (2017-2022)
  • Table 20. Anti-inflammatory Drugs Delayed-Release Tablet , by Region USD Million (2017-2022)
  • Table 21. Anti-inflammatory Drugs Liquid , by Region USD Million (2017-2022)
  • Table 22. Anti-inflammatory Drugs Topical Cream , by Region USD Million (2017-2022)
  • Table 23. Anti-inflammatory Drugs Paste , by Region USD Million (2017-2022)
  • Table 24. Anti-inflammatory Drugs Injection , by Region USD Million (2017-2022)
  • Table 25. Anti-inflammatory Drugs: by Distribution Channel(USD Million)
  • Table 26. Anti-inflammatory Drugs Online , by Region USD Million (2017-2022)
  • Table 27. Anti-inflammatory Drugs Offline , by Region USD Million (2017-2022)
  • Table 28. Anti-inflammatory Drugs: by Method(USD Million)
  • Table 29. Anti-inflammatory Drugs Over-The-Counter , by Region USD Million (2017-2022)
  • Table 30. Anti-inflammatory Drugs Prescription Medications , by Region USD Million (2017-2022)
  • Table 31. Anti-inflammatory Drugs: by Drug Class(USD Million)
  • Table 32. Anti-inflammatory Drugs Anti-Inflammatory Biologics , by Region USD Million (2017-2022)
  • Table 33. Anti-inflammatory Drugs Nonsteroidal anti-inflammatory drugs (NSAIDs) , by Region USD Million (2017-2022)
  • Table 34. Anti-inflammatory Drugs Corticosteroids , by Region USD Million (2017-2022)
  • Table 35. Anti-inflammatory Drugs Immune-selective anti-inflammatory derivative (ImSAID) , by Region USD Million (2017-2022)
  • Table 36. Anti-inflammatory Drugs Others , by Region USD Million (2017-2022)
  • Table 37. South America Anti-inflammatory Drugs, by Country USD Million (2017-2022)
  • Table 38. South America Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 39. South America Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 40. South America Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 41. South America Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 42. South America Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 43. South America Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 44. South America Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 45. Brazil Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 46. Brazil Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 47. Brazil Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 48. Brazil Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 49. Brazil Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 50. Brazil Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 51. Brazil Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 52. Argentina Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 53. Argentina Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 54. Argentina Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 55. Argentina Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 56. Argentina Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 57. Argentina Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 58. Argentina Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 59. Rest of South America Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 60. Rest of South America Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 61. Rest of South America Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 62. Rest of South America Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 63. Rest of South America Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 64. Rest of South America Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 65. Rest of South America Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 66. Asia Pacific Anti-inflammatory Drugs, by Country USD Million (2017-2022)
  • Table 67. Asia Pacific Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 68. Asia Pacific Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 69. Asia Pacific Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 70. Asia Pacific Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 71. Asia Pacific Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 72. Asia Pacific Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 73. Asia Pacific Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 74. China Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 75. China Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 76. China Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 77. China Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 78. China Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 79. China Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 80. China Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 81. Japan Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 82. Japan Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 83. Japan Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 84. Japan Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 85. Japan Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 86. Japan Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 87. Japan Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 88. India Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 89. India Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 90. India Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 91. India Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 92. India Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 93. India Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 94. India Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 95. South Korea Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 96. South Korea Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 97. South Korea Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 98. South Korea Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 99. South Korea Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 100. South Korea Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 101. South Korea Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 102. Taiwan Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 103. Taiwan Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 104. Taiwan Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 105. Taiwan Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 106. Taiwan Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 107. Taiwan Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 108. Taiwan Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 109. Australia Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 110. Australia Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 111. Australia Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 112. Australia Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 113. Australia Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 114. Australia Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 115. Australia Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 116. Rest of Asia-Pacific Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 117. Rest of Asia-Pacific Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 118. Rest of Asia-Pacific Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 119. Rest of Asia-Pacific Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 120. Rest of Asia-Pacific Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 121. Rest of Asia-Pacific Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 122. Rest of Asia-Pacific Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 123. Europe Anti-inflammatory Drugs, by Country USD Million (2017-2022)
  • Table 124. Europe Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 125. Europe Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 126. Europe Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 127. Europe Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 128. Europe Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 129. Europe Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 130. Europe Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 131. Germany Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 132. Germany Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 133. Germany Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 134. Germany Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 135. Germany Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 136. Germany Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 137. Germany Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 138. France Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 139. France Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 140. France Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 141. France Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 142. France Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 143. France Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 144. France Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 145. Italy Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 146. Italy Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 147. Italy Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 148. Italy Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 149. Italy Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 150. Italy Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 151. Italy Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 152. United Kingdom Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 153. United Kingdom Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 154. United Kingdom Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 155. United Kingdom Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 156. United Kingdom Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 157. United Kingdom Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 158. United Kingdom Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 159. Netherlands Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 160. Netherlands Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 161. Netherlands Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 162. Netherlands Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 163. Netherlands Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 164. Netherlands Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 165. Netherlands Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 166. Rest of Europe Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 167. Rest of Europe Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 168. Rest of Europe Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 169. Rest of Europe Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 170. Rest of Europe Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 171. Rest of Europe Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 172. Rest of Europe Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 173. MEA Anti-inflammatory Drugs, by Country USD Million (2017-2022)
  • Table 174. MEA Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 175. MEA Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 176. MEA Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 177. MEA Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 178. MEA Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 179. MEA Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 180. MEA Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 181. Middle East Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 182. Middle East Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 183. Middle East Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 184. Middle East Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 185. Middle East Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 186. Middle East Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 187. Middle East Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 188. Africa Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 189. Africa Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 190. Africa Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 191. Africa Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 192. Africa Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 193. Africa Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 194. Africa Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 195. North America Anti-inflammatory Drugs, by Country USD Million (2017-2022)
  • Table 196. North America Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 197. North America Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 198. North America Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 199. North America Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 200. North America Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 201. North America Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 202. North America Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 203. United States Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 204. United States Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 205. United States Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 206. United States Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 207. United States Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 208. United States Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 209. United States Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 210. Canada Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 211. Canada Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 212. Canada Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 213. Canada Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 214. Canada Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 215. Canada Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 216. Canada Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 217. Mexico Anti-inflammatory Drugs, by Type USD Million (2017-2022)
  • Table 218. Mexico Anti-inflammatory Drugs, by Application USD Million (2017-2022)
  • Table 219. Mexico Anti-inflammatory Drugs, by Treatment USD Million (2017-2022)
  • Table 220. Mexico Anti-inflammatory Drugs, by Form USD Million (2017-2022)
  • Table 221. Mexico Anti-inflammatory Drugs, by Distribution Channel USD Million (2017-2022)
  • Table 222. Mexico Anti-inflammatory Drugs, by Method USD Million (2017-2022)
  • Table 223. Mexico Anti-inflammatory Drugs, by Drug Class USD Million (2017-2022)
  • Table 224. Anti-inflammatory Drugs Sales: by Type(K Units)
  • Table 225. Anti-inflammatory Drugs Sales Aspirin, , by Region K Units (2017-2022)
  • Table 226. Anti-inflammatory Drugs Sales Ibuprofen , by Region K Units (2017-2022)
  • Table 227. Anti-inflammatory Drugs Sales Naproxen , by Region K Units (2017-2022)
  • Table 228. Anti-inflammatory Drugs Sales COX-2 Inhibitors , by Region K Units (2017-2022)
  • Table 229. Anti-inflammatory Drugs Sales Other , by Region K Units (2017-2022)
  • Table 230. Anti-inflammatory Drugs Sales: by Application(K Units)
  • Table 231. Anti-inflammatory Drugs Sales Skin Rashes , by Region K Units (2017-2022)
  • Table 232. Anti-inflammatory Drugs Sales Chronic Arthritis , by Region K Units (2017-2022)
  • Table 233. Anti-inflammatory Drugs Sales Other , by Region K Units (2017-2022)
  • Table 234. Anti-inflammatory Drugs Sales: by Treatment(K Units)
  • Table 235. Anti-inflammatory Drugs Sales Arthritis , by Region K Units (2017-2022)
  • Table 236. Anti-inflammatory Drugs Sales Chronic obstructive pulmonary disease (COPD) , by Region K Units (2017-2022)
  • Table 237. Anti-inflammatory Drugs Sales Multiple Sclerosis , by Region K Units (2017-2022)
  • Table 238. Anti-inflammatory Drugs Sales Inflammatory bowel disease (IBD) , by Region K Units (2017-2022)
  • Table 239. Anti-inflammatory Drugs Sales Asthma , by Region K Units (2017-2022)
  • Table 240. Anti-inflammatory Drugs Sales Others , by Region K Units (2017-2022)
  • Table 241. Anti-inflammatory Drugs Sales: by Form(K Units)
  • Table 242. Anti-inflammatory Drugs Sales Regular Tablet , by Region K Units (2017-2022)
  • Table 243. Anti-inflammatory Drugs Sales Delayed-Release Tablet , by Region K Units (2017-2022)
  • Table 244. Anti-inflammatory Drugs Sales Liquid , by Region K Units (2017-2022)
  • Table 245. Anti-inflammatory Drugs Sales Topical Cream , by Region K Units (2017-2022)
  • Table 246. Anti-inflammatory Drugs Sales Paste , by Region K Units (2017-2022)
  • Table 247. Anti-inflammatory Drugs Sales Injection , by Region K Units (2017-2022)
  • Table 248. Anti-inflammatory Drugs Sales: by Distribution Channel(K Units)
  • Table 249. Anti-inflammatory Drugs Sales Online , by Region K Units (2017-2022)
  • Table 250. Anti-inflammatory Drugs Sales Offline , by Region K Units (2017-2022)
  • Table 251. Anti-inflammatory Drugs Sales: by Method(K Units)
  • Table 252. Anti-inflammatory Drugs Sales Over-The-Counter , by Region K Units (2017-2022)
  • Table 253. Anti-inflammatory Drugs Sales Prescription Medications , by Region K Units (2017-2022)
  • Table 254. Anti-inflammatory Drugs Sales: by Drug Class(K Units)
  • Table 255. Anti-inflammatory Drugs Sales Anti-Inflammatory Biologics , by Region K Units (2017-2022)
  • Table 256. Anti-inflammatory Drugs Sales Nonsteroidal anti-inflammatory drugs (NSAIDs) , by Region K Units (2017-2022)
  • Table 257. Anti-inflammatory Drugs Sales Corticosteroids , by Region K Units (2017-2022)
  • Table 258. Anti-inflammatory Drugs Sales Immune-selective anti-inflammatory derivative (ImSAID) , by Region K Units (2017-2022)
  • Table 259. Anti-inflammatory Drugs Sales Others , by Region K Units (2017-2022)
  • Table 260. South America Anti-inflammatory Drugs Sales, by Country K Units (2017-2022)
  • Table 261. South America Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 262. South America Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 263. South America Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 264. South America Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 265. South America Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 266. South America Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 267. South America Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 268. Brazil Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 269. Brazil Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 270. Brazil Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 271. Brazil Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 272. Brazil Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 273. Brazil Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 274. Brazil Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 275. Argentina Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 276. Argentina Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 277. Argentina Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 278. Argentina Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 279. Argentina Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 280. Argentina Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 281. Argentina Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 282. Rest of South America Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 283. Rest of South America Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 284. Rest of South America Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 285. Rest of South America Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 286. Rest of South America Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 287. Rest of South America Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 288. Rest of South America Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 289. Asia Pacific Anti-inflammatory Drugs Sales, by Country K Units (2017-2022)
  • Table 290. Asia Pacific Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 291. Asia Pacific Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 292. Asia Pacific Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 293. Asia Pacific Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 294. Asia Pacific Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 295. Asia Pacific Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 296. Asia Pacific Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 297. China Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 298. China Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 299. China Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 300. China Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 301. China Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 302. China Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 303. China Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 304. Japan Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 305. Japan Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 306. Japan Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 307. Japan Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 308. Japan Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 309. Japan Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 310. Japan Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 311. India Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 312. India Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 313. India Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 314. India Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 315. India Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 316. India Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 317. India Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 318. South Korea Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 319. South Korea Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 320. South Korea Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 321. South Korea Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 322. South Korea Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 323. South Korea Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 324. South Korea Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 325. Taiwan Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 326. Taiwan Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 327. Taiwan Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 328. Taiwan Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 329. Taiwan Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 330. Taiwan Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 331. Taiwan Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 332. Australia Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 333. Australia Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 334. Australia Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 335. Australia Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 336. Australia Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 337. Australia Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 338. Australia Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 339. Rest of Asia-Pacific Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 340. Rest of Asia-Pacific Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 341. Rest of Asia-Pacific Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 342. Rest of Asia-Pacific Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 343. Rest of Asia-Pacific Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 344. Rest of Asia-Pacific Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 345. Rest of Asia-Pacific Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 346. Europe Anti-inflammatory Drugs Sales, by Country K Units (2017-2022)
  • Table 347. Europe Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 348. Europe Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 349. Europe Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 350. Europe Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 351. Europe Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 352. Europe Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 353. Europe Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 354. Germany Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 355. Germany Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 356. Germany Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 357. Germany Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 358. Germany Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 359. Germany Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 360. Germany Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 361. France Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 362. France Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 363. France Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 364. France Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 365. France Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 366. France Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 367. France Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 368. Italy Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 369. Italy Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 370. Italy Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 371. Italy Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 372. Italy Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 373. Italy Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 374. Italy Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 375. United Kingdom Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 376. United Kingdom Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 377. United Kingdom Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 378. United Kingdom Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 379. United Kingdom Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 380. United Kingdom Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 381. United Kingdom Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 382. Netherlands Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 383. Netherlands Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 384. Netherlands Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 385. Netherlands Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 386. Netherlands Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 387. Netherlands Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 388. Netherlands Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 389. Rest of Europe Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 390. Rest of Europe Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 391. Rest of Europe Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 392. Rest of Europe Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 393. Rest of Europe Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 394. Rest of Europe Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 395. Rest of Europe Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 396. MEA Anti-inflammatory Drugs Sales, by Country K Units (2017-2022)
  • Table 397. MEA Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 398. MEA Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 399. MEA Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 400. MEA Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 401. MEA Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 402. MEA Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 403. MEA Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 404. Middle East Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 405. Middle East Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 406. Middle East Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 407. Middle East Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 408. Middle East Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 409. Middle East Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 410. Middle East Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 411. Africa Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 412. Africa Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 413. Africa Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 414. Africa Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 415. Africa Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 416. Africa Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 417. Africa Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 418. North America Anti-inflammatory Drugs Sales, by Country K Units (2017-2022)
  • Table 419. North America Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 420. North America Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 421. North America Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 422. North America Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 423. North America Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 424. North America Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 425. North America Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 426. United States Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 427. United States Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 428. United States Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 429. United States Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 430. United States Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 431. United States Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 432. United States Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 433. Canada Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 434. Canada Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 435. Canada Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 436. Canada Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 437. Canada Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 438. Canada Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 439. Canada Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 440. Mexico Anti-inflammatory Drugs Sales, by Type K Units (2017-2022)
  • Table 441. Mexico Anti-inflammatory Drugs Sales, by Application K Units (2017-2022)
  • Table 442. Mexico Anti-inflammatory Drugs Sales, by Treatment K Units (2017-2022)
  • Table 443. Mexico Anti-inflammatory Drugs Sales, by Form K Units (2017-2022)
  • Table 444. Mexico Anti-inflammatory Drugs Sales, by Distribution Channel K Units (2017-2022)
  • Table 445. Mexico Anti-inflammatory Drugs Sales, by Method K Units (2017-2022)
  • Table 446. Mexico Anti-inflammatory Drugs Sales, by Drug Class K Units (2017-2022)
  • Table 447. Anti-inflammatory Drugs: by Type(USD/Units)
  • Table 448. Company Basic Information, Sales Area and Its Competitors
  • Table 449. Company Basic Information, Sales Area and Its Competitors
  • Table 450. Company Basic Information, Sales Area and Its Competitors
  • Table 451. Company Basic Information, Sales Area and Its Competitors
  • Table 452. Company Basic Information, Sales Area and Its Competitors
  • Table 453. Company Basic Information, Sales Area and Its Competitors
  • Table 454. Company Basic Information, Sales Area and Its Competitors
  • Table 455. Company Basic Information, Sales Area and Its Competitors
  • Table 456. Company Basic Information, Sales Area and Its Competitors
  • Table 457. Company Basic Information, Sales Area and Its Competitors
  • Table 458. Anti-inflammatory Drugs: by Type(USD Million)
  • Table 459. Anti-inflammatory Drugs Aspirin, , by Region USD Million (2023-2028)
  • Table 460. Anti-inflammatory Drugs Ibuprofen , by Region USD Million (2023-2028)
  • Table 461. Anti-inflammatory Drugs Naproxen , by Region USD Million (2023-2028)
  • Table 462. Anti-inflammatory Drugs COX-2 Inhibitors , by Region USD Million (2023-2028)
  • Table 463. Anti-inflammatory Drugs Other , by Region USD Million (2023-2028)
  • Table 464. Anti-inflammatory Drugs: by Application(USD Million)
  • Table 465. Anti-inflammatory Drugs Skin Rashes , by Region USD Million (2023-2028)
  • Table 466. Anti-inflammatory Drugs Chronic Arthritis , by Region USD Million (2023-2028)
  • Table 467. Anti-inflammatory Drugs Other , by Region USD Million (2023-2028)
  • Table 468. Anti-inflammatory Drugs: by Treatment(USD Million)
  • Table 469. Anti-inflammatory Drugs Arthritis , by Region USD Million (2023-2028)
  • Table 470. Anti-inflammatory Drugs Chronic obstructive pulmonary disease (COPD) , by Region USD Million (2023-2028)
  • Table 471. Anti-inflammatory Drugs Multiple Sclerosis , by Region USD Million (2023-2028)
  • Table 472. Anti-inflammatory Drugs Inflammatory bowel disease (IBD) , by Region USD Million (2023-2028)
  • Table 473. Anti-inflammatory Drugs Asthma , by Region USD Million (2023-2028)
  • Table 474. Anti-inflammatory Drugs Others , by Region USD Million (2023-2028)
  • Table 475. Anti-inflammatory Drugs: by Form(USD Million)
  • Table 476. Anti-inflammatory Drugs Regular Tablet , by Region USD Million (2023-2028)
  • Table 477. Anti-inflammatory Drugs Delayed-Release Tablet , by Region USD Million (2023-2028)
  • Table 478. Anti-inflammatory Drugs Liquid , by Region USD Million (2023-2028)
  • Table 479. Anti-inflammatory Drugs Topical Cream , by Region USD Million (2023-2028)
  • Table 480. Anti-inflammatory Drugs Paste , by Region USD Million (2023-2028)
  • Table 481. Anti-inflammatory Drugs Injection , by Region USD Million (2023-2028)
  • Table 482. Anti-inflammatory Drugs: by Distribution Channel(USD Million)
  • Table 483. Anti-inflammatory Drugs Online , by Region USD Million (2023-2028)
  • Table 484. Anti-inflammatory Drugs Offline , by Region USD Million (2023-2028)
  • Table 485. Anti-inflammatory Drugs: by Method(USD Million)
  • Table 486. Anti-inflammatory Drugs Over-The-Counter , by Region USD Million (2023-2028)
  • Table 487. Anti-inflammatory Drugs Prescription Medications , by Region USD Million (2023-2028)
  • Table 488. Anti-inflammatory Drugs: by Drug Class(USD Million)
  • Table 489. Anti-inflammatory Drugs Anti-Inflammatory Biologics , by Region USD Million (2023-2028)
  • Table 490. Anti-inflammatory Drugs Nonsteroidal anti-inflammatory drugs (NSAIDs) , by Region USD Million (2023-2028)
  • Table 491. Anti-inflammatory Drugs Corticosteroids , by Region USD Million (2023-2028)
  • Table 492. Anti-inflammatory Drugs Immune-selective anti-inflammatory derivative (ImSAID) , by Region USD Million (2023-2028)
  • Table 493. Anti-inflammatory Drugs Others , by Region USD Million (2023-2028)
  • Table 494. South America Anti-inflammatory Drugs, by Country USD Million (2023-2028)
  • Table 495. South America Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 496. South America Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 497. South America Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 498. South America Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 499. South America Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 500. South America Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 501. South America Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 502. Brazil Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 503. Brazil Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 504. Brazil Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 505. Brazil Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 506. Brazil Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 507. Brazil Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 508. Brazil Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 509. Argentina Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 510. Argentina Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 511. Argentina Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 512. Argentina Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 513. Argentina Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 514. Argentina Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 515. Argentina Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 516. Rest of South America Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 517. Rest of South America Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 518. Rest of South America Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 519. Rest of South America Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 520. Rest of South America Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 521. Rest of South America Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 522. Rest of South America Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 523. Asia Pacific Anti-inflammatory Drugs, by Country USD Million (2023-2028)
  • Table 524. Asia Pacific Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 525. Asia Pacific Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 526. Asia Pacific Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 527. Asia Pacific Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 528. Asia Pacific Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 529. Asia Pacific Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 530. Asia Pacific Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 531. China Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 532. China Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 533. China Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 534. China Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 535. China Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 536. China Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 537. China Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 538. Japan Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 539. Japan Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 540. Japan Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 541. Japan Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 542. Japan Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 543. Japan Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 544. Japan Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 545. India Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 546. India Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 547. India Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 548. India Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 549. India Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 550. India Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 551. India Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 552. South Korea Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 553. South Korea Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 554. South Korea Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 555. South Korea Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 556. South Korea Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 557. South Korea Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 558. South Korea Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 559. Taiwan Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 560. Taiwan Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 561. Taiwan Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 562. Taiwan Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 563. Taiwan Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 564. Taiwan Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 565. Taiwan Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 566. Australia Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 567. Australia Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 568. Australia Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 569. Australia Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 570. Australia Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 571. Australia Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 572. Australia Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 573. Rest of Asia-Pacific Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 574. Rest of Asia-Pacific Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 575. Rest of Asia-Pacific Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 576. Rest of Asia-Pacific Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 577. Rest of Asia-Pacific Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 578. Rest of Asia-Pacific Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 579. Rest of Asia-Pacific Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 580. Europe Anti-inflammatory Drugs, by Country USD Million (2023-2028)
  • Table 581. Europe Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 582. Europe Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 583. Europe Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 584. Europe Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 585. Europe Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 586. Europe Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 587. Europe Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 588. Germany Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 589. Germany Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 590. Germany Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 591. Germany Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 592. Germany Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 593. Germany Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 594. Germany Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 595. France Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 596. France Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 597. France Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 598. France Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 599. France Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 600. France Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 601. France Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 602. Italy Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 603. Italy Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 604. Italy Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 605. Italy Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 606. Italy Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 607. Italy Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 608. Italy Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 609. United Kingdom Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 610. United Kingdom Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 611. United Kingdom Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 612. United Kingdom Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 613. United Kingdom Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 614. United Kingdom Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 615. United Kingdom Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 616. Netherlands Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 617. Netherlands Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 618. Netherlands Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 619. Netherlands Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 620. Netherlands Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 621. Netherlands Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 622. Netherlands Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 623. Rest of Europe Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 624. Rest of Europe Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 625. Rest of Europe Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 626. Rest of Europe Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 627. Rest of Europe Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 628. Rest of Europe Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 629. Rest of Europe Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 630. MEA Anti-inflammatory Drugs, by Country USD Million (2023-2028)
  • Table 631. MEA Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 632. MEA Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 633. MEA Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 634. MEA Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 635. MEA Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 636. MEA Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 637. MEA Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 638. Middle East Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 639. Middle East Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 640. Middle East Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 641. Middle East Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 642. Middle East Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 643. Middle East Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 644. Middle East Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 645. Africa Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 646. Africa Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 647. Africa Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 648. Africa Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 649. Africa Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 650. Africa Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 651. Africa Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 652. North America Anti-inflammatory Drugs, by Country USD Million (2023-2028)
  • Table 653. North America Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 654. North America Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 655. North America Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 656. North America Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 657. North America Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 658. North America Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 659. North America Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 660. United States Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 661. United States Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 662. United States Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 663. United States Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 664. United States Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 665. United States Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 666. United States Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 667. Canada Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 668. Canada Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 669. Canada Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 670. Canada Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 671. Canada Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 672. Canada Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 673. Canada Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 674. Mexico Anti-inflammatory Drugs, by Type USD Million (2023-2028)
  • Table 675. Mexico Anti-inflammatory Drugs, by Application USD Million (2023-2028)
  • Table 676. Mexico Anti-inflammatory Drugs, by Treatment USD Million (2023-2028)
  • Table 677. Mexico Anti-inflammatory Drugs, by Form USD Million (2023-2028)
  • Table 678. Mexico Anti-inflammatory Drugs, by Distribution Channel USD Million (2023-2028)
  • Table 679. Mexico Anti-inflammatory Drugs, by Method USD Million (2023-2028)
  • Table 680. Mexico Anti-inflammatory Drugs, by Drug Class USD Million (2023-2028)
  • Table 681. Anti-inflammatory Drugs Sales: by Type(K Units)
  • Table 682. Anti-inflammatory Drugs Sales Aspirin, , by Region K Units (2023-2028)
  • Table 683. Anti-inflammatory Drugs Sales Ibuprofen , by Region K Units (2023-2028)
  • Table 684. Anti-inflammatory Drugs Sales Naproxen , by Region K Units (2023-2028)
  • Table 685. Anti-inflammatory Drugs Sales COX-2 Inhibitors , by Region K Units (2023-2028)
  • Table 686. Anti-inflammatory Drugs Sales Other , by Region K Units (2023-2028)
  • Table 687. Anti-inflammatory Drugs Sales: by Application(K Units)
  • Table 688. Anti-inflammatory Drugs Sales Skin Rashes , by Region K Units (2023-2028)
  • Table 689. Anti-inflammatory Drugs Sales Chronic Arthritis , by Region K Units (2023-2028)
  • Table 690. Anti-inflammatory Drugs Sales Other , by Region K Units (2023-2028)
  • Table 691. Anti-inflammatory Drugs Sales: by Treatment(K Units)
  • Table 692. Anti-inflammatory Drugs Sales Arthritis , by Region K Units (2023-2028)
  • Table 693. Anti-inflammatory Drugs Sales Chronic obstructive pulmonary disease (COPD) , by Region K Units (2023-2028)
  • Table 694. Anti-inflammatory Drugs Sales Multiple Sclerosis , by Region K Units (2023-2028)
  • Table 695. Anti-inflammatory Drugs Sales Inflammatory bowel disease (IBD) , by Region K Units (2023-2028)
  • Table 696. Anti-inflammatory Drugs Sales Asthma , by Region K Units (2023-2028)
  • Table 697. Anti-inflammatory Drugs Sales Others , by Region K Units (2023-2028)
  • Table 698. Anti-inflammatory Drugs Sales: by Form(K Units)
  • Table 699. Anti-inflammatory Drugs Sales Regular Tablet , by Region K Units (2023-2028)
  • Table 700. Anti-inflammatory Drugs Sales Delayed-Release Tablet , by Region K Units (2023-2028)
  • Table 701. Anti-inflammatory Drugs Sales Liquid , by Region K Units (2023-2028)
  • Table 702. Anti-inflammatory Drugs Sales Topical Cream , by Region K Units (2023-2028)
  • Table 703. Anti-inflammatory Drugs Sales Paste , by Region K Units (2023-2028)
  • Table 704. Anti-inflammatory Drugs Sales Injection , by Region K Units (2023-2028)
  • Table 705. Anti-inflammatory Drugs Sales: by Distribution Channel(K Units)
  • Table 706. Anti-inflammatory Drugs Sales Online , by Region K Units (2023-2028)
  • Table 707. Anti-inflammatory Drugs Sales Offline , by Region K Units (2023-2028)
  • Table 708. Anti-inflammatory Drugs Sales: by Method(K Units)
  • Table 709. Anti-inflammatory Drugs Sales Over-The-Counter , by Region K Units (2023-2028)
  • Table 710. Anti-inflammatory Drugs Sales Prescription Medications , by Region K Units (2023-2028)
  • Table 711. Anti-inflammatory Drugs Sales: by Drug Class(K Units)
  • Table 712. Anti-inflammatory Drugs Sales Anti-Inflammatory Biologics , by Region K Units (2023-2028)
  • Table 713. Anti-inflammatory Drugs Sales Nonsteroidal anti-inflammatory drugs (NSAIDs) , by Region K Units (2023-2028)
  • Table 714. Anti-inflammatory Drugs Sales Corticosteroids , by Region K Units (2023-2028)
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Anti-inflammatory Drugs: by Type USD Million (2017-2022)
  • Figure 5. Global Anti-inflammatory Drugs: by Application USD Million (2017-2022)
  • Figure 6. Global Anti-inflammatory Drugs: by Treatment USD Million (2017-2022)
  • Figure 7. Global Anti-inflammatory Drugs: by Form USD Million (2017-2022)
  • Figure 8. Global Anti-inflammatory Drugs: by Distribution Channel USD Million (2017-2022)
  • Figure 9. Global Anti-inflammatory Drugs: by Method USD Million (2017-2022)
  • Figure 10. Global Anti-inflammatory Drugs: by Drug Class USD Million (2017-2022)
  • Figure 11. South America Anti-inflammatory Drugs Share (%), by Country
  • Figure 12. Asia Pacific Anti-inflammatory Drugs Share (%), by Country
  • Figure 13. Europe Anti-inflammatory Drugs Share (%), by Country
  • Figure 14. MEA Anti-inflammatory Drugs Share (%), by Country
  • Figure 15. North America Anti-inflammatory Drugs Share (%), by Country
  • Figure 16. Global Anti-inflammatory Drugs: by Type K Units (2017-2022)
  • Figure 17. Global Anti-inflammatory Drugs: by Application K Units (2017-2022)
  • Figure 18. Global Anti-inflammatory Drugs: by Treatment K Units (2017-2022)
  • Figure 19. Global Anti-inflammatory Drugs: by Form K Units (2017-2022)
  • Figure 20. Global Anti-inflammatory Drugs: by Distribution Channel K Units (2017-2022)
  • Figure 21. Global Anti-inflammatory Drugs: by Method K Units (2017-2022)
  • Figure 22. Global Anti-inflammatory Drugs: by Drug Class K Units (2017-2022)
  • Figure 23. South America Anti-inflammatory Drugs Share (%), by Country
  • Figure 24. Asia Pacific Anti-inflammatory Drugs Share (%), by Country
  • Figure 25. Europe Anti-inflammatory Drugs Share (%), by Country
  • Figure 26. MEA Anti-inflammatory Drugs Share (%), by Country
  • Figure 27. North America Anti-inflammatory Drugs Share (%), by Country
  • Figure 28. Global Anti-inflammatory Drugs: by Type USD/Units (2017-2022)
  • Figure 29. Global Anti-inflammatory Drugs share by Players 2022 (%)
  • Figure 30. Global Anti-inflammatory Drugs share by Players (Top 3) 2022(%)
  • Figure 31. Global Anti-inflammatory Drugs share by Players (Top 5) 2022(%)
  • Figure 32. BCG Matrix for key Companies
  • Figure 33. Roche (Switzerland) Revenue, Net Income and Gross profit
  • Figure 34. Roche (Switzerland) Revenue: by Geography 2022
  • Figure 35. Abbott Laboratories (United States) Revenue, Net Income and Gross profit
  • Figure 36. Abbott Laboratories (United States) Revenue: by Geography 2022
  • Figure 37. Johnson & Johnson (United States) Revenue, Net Income and Gross profit
  • Figure 38. Johnson & Johnson (United States) Revenue: by Geography 2022
  • Figure 39. Merck & Co. (United States) Revenue, Net Income and Gross profit
  • Figure 40. Merck & Co. (United States) Revenue: by Geography 2022
  • Figure 41. Pfizer (United States) Revenue, Net Income and Gross profit
  • Figure 42. Pfizer (United States) Revenue: by Geography 2022
  • Figure 43. Amgen(United States) Revenue, Net Income and Gross profit
  • Figure 44. Amgen(United States) Revenue: by Geography 2022
  • Figure 45. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 46. Sanofi (France) Revenue: by Geography 2022
  • Figure 47. Novartis (Switzerland) Revenue, Net Income and Gross profit
  • Figure 48. Novartis (Switzerland) Revenue: by Geography 2022
  • Figure 49. Eli Lilly and Company(United States) Revenue, Net Income and Gross profit
  • Figure 50. Eli Lilly and Company(United States) Revenue: by Geography 2022
  • Figure 51. Amgen(United States) Revenue, Net Income and Gross profit
  • Figure 52. Amgen(United States) Revenue: by Geography 2022
  • Figure 53. Global Anti-inflammatory Drugs: by Type USD Million (2023-2028)
  • Figure 54. Global Anti-inflammatory Drugs: by Application USD Million (2023-2028)
  • Figure 55. Global Anti-inflammatory Drugs: by Treatment USD Million (2023-2028)
  • Figure 56. Global Anti-inflammatory Drugs: by Form USD Million (2023-2028)
  • Figure 57. Global Anti-inflammatory Drugs: by Distribution Channel USD Million (2023-2028)
  • Figure 58. Global Anti-inflammatory Drugs: by Method USD Million (2023-2028)
  • Figure 59. Global Anti-inflammatory Drugs: by Drug Class USD Million (2023-2028)
  • Figure 60. South America Anti-inflammatory Drugs Share (%), by Country
  • Figure 61. Asia Pacific Anti-inflammatory Drugs Share (%), by Country
  • Figure 62. Europe Anti-inflammatory Drugs Share (%), by Country
  • Figure 63. MEA Anti-inflammatory Drugs Share (%), by Country
  • Figure 64. North America Anti-inflammatory Drugs Share (%), by Country
  • Figure 65. Global Anti-inflammatory Drugs: by Type K Units (2023-2028)
  • Figure 66. Global Anti-inflammatory Drugs: by Application K Units (2023-2028)
  • Figure 67. Global Anti-inflammatory Drugs: by Treatment K Units (2023-2028)
  • Figure 68. Global Anti-inflammatory Drugs: by Form K Units (2023-2028)
  • Figure 69. Global Anti-inflammatory Drugs: by Distribution Channel K Units (2023-2028)
  • Figure 70. Global Anti-inflammatory Drugs: by Method K Units (2023-2028)
  • Figure 71. Global Anti-inflammatory Drugs: by Drug Class K Units (2023-2028)
  • Figure 72. South America Anti-inflammatory Drugs Share (%), by Country
  • Figure 73. Asia Pacific Anti-inflammatory Drugs Share (%), by Country
  • Figure 74. Europe Anti-inflammatory Drugs Share (%), by Country
  • Figure 75. MEA Anti-inflammatory Drugs Share (%), by Country
  • Figure 76. North America Anti-inflammatory Drugs Share (%), by Country
  • Figure 77. Global Anti-inflammatory Drugs: by Type USD/Units (2023-2028)
List of companies from research coverage that are profiled in the study
  • Roche (Switzerland)
  • Abbott Laboratories (United States)
  • Johnson & Johnson (United States)
  • Merck & Co. (United States)
  • Pfizer (United States)
  • Amgen(United States)
  • Sanofi (France)
  • Novartis (Switzerland)
  • Eli Lilly and Company(United States)
  • Amgen(United States)
Additional players considered in the study are as follows:
Bayer (Germany) , Novacap (Canada)
Select User Access Type

Key Highlights of Report


Apr 2023 217 Pages 56 Tables Base Year: 2022 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Anti-inflammatory Drugs Quantitative research analysis
Global Anti-inflammatory Drugs Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as Roche (Switzerland), Abbott Laboratories (United States), Johnson & Johnson (United States), Merck & Co. (United States), Pfizer (United States), Amgen(United States), Sanofi (France), Novartis (Switzerland), Eli Lilly and Company(United States) and Amgen(United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"" is seen as one of major influencing trends for Anti-inflammatory Drugs Market during projected period 2022-2028.
The Anti-inflammatory Drugs market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Anti-inflammatory Drugs Report?

Have a Query? Click Here

Other Related Reports

RTD Soy Milk Comprehensive Study by Type (Whole Soybeans Based, Full-Fat Soy Flour Based), Distribution Channels (Offline Channel, Online Channel), By Flavor (Soya Chocolate, Soya Honeydew, Soya Stra...
$ 3800
Interior Paints Comprehensive Study by Type (Matte Paint, Matte Enamel, Satin, Eggshell, Semi-Gloss, Gloss Paint), Application (Commercial, Household), Distribution Channel (Online Retail, Offline Re...
$ 3500
Scientific and Technical Publication Comprehensive Study by Type (Books, Journals, E-Books, Online Services), End User (Students, Professionals) Players and Region - Global Market Outlook to 2027
$ 3500
E-Prescribing Comprehensive Study by Type (Stand-Alone Systems, Integrated Systems), Application (Hospital, Office-based physician), Delivery Mode (Web-based, On-premise/licensed, Cloud-based), Comp...
$ 3350
Spreadsheet Software Comprehensive Study by Type (Cloud based, On premise), Application (SMEs, Large Enterprises), End User (Individual, Enterprises) Players and Region - Global Market Outlook to 202...
$ 3800
Biodegradable Tableware Comprehensive Study by Type (Plates, Bowls, Cups, Cutlery, Others), Application (Commercial Use, Household Use), Distribution Channel (E-commerce, Supermarkets/Hypermarkets, R...
$ 3800